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ABSTRACT 
Background: L-dopa responsiveness in Parkinson's disease (PD) varies, but the clinical correlates and 
significance of this are ill-defined. 
Methods: Patients were assessed before and after their usual morning L-dopa dose, using the MDS 
Unified PD Rating Scale Part 3 (MDS UPDRS 3), and rated as definite responders (≥24.5% improvement) 
or limited re-sponders (< 24.5%). 
Results: 1007 cases, mean age 66.1 years (SD 9.1) at diagnosis, were assessed 3.4 (SD 0.9) years after 
diagnosis. The L-dopa response was definite in 614 cases (61.0%), median reduction in MDS UPDRS 3 
scores was 42.0%,(IQR 33.3, 53.1), and was limited in 393 cases (39.0%), median reduction in MDS 
UPDRS 3 scores 11.5% (IQR 4.3, 18.2). Definite responders were younger (66.3 years at study entry, 
SD 9.3) than limited responders (69.2 years, SD 8.4, p < 0.001). The MDS UPDRS 3 score at study entry 
in definite responders (21.0, SD 10.5) was significantly lower than in limited responders (24.7, SD 13.4, 
p < 0.001). The MDS UPDRS 3 increase over 18 months was less in definite responders at 3.0 (SD 10.4), 
compared to limited responders (6.4, SD 11.0, p < 0.001). The levodopa equivalent daily dose (LEDD) 
was not significantly different at study entry (definite responders 317 mg, SD 199, vs limited 
responders 305 mg, SD 191, p = 0.53). However, LEDD was significantly higher at the time of the L-
dopa challenge test in definite responders (541 mg, SD 293) compared to limited responders (485 mg, 
SD 215, p = 0.01). Responsiveness to L-dopa was unaffected by the challenge test dose (p = 0.54). 
Conclusions: The main determinants of variation in the L-dopa response in early PD are age and motor 
severity. A limited L-dopa response is associated with faster motor progression. 
 
1. Introduction 
The phenotypic heterogeneity of Parkinson's disease (PD) is well recognized [1], and includes 
variability in L-dopa responsiveness [2,3]. While an excellent [4] or clear and dramatic [5] response to 
L-dopa is a supportive feature in the diagnostic criteria for idiopathic PD, a less marked response does 
not rule out the diagnosis of PD [4,5]. A number of studies have shown variation in the response to 
either an acute L-dopa challenge dose [6–8], or chronic L-dopa therapy [2,4,6,8] both in clinically 
diagnosed PD [2,4,6,8], and in pathologically confirmed cases [4]. However, the clinical correlates and 
significance of this variation in response are not clearly defined. We wished to explore in detail, in a 
large cohort of recently diagnosed PD patients, which clinical characteristics are associated with the 
level of motor responsiveness to L-dopa. We hypothesised that a limited motor response to L-dopa 
was a likely contributor to variation in the motor progression rate, which could be measured by 
prospective observation. We also set out to ex-amine whether comorbidities (e.g. cerebrovascular 
disease) influenced the L-dopa motor response. 
2. Methods 
Tracking Parkinson's is a prospective observational multicentre study that has recruited from 72 
centres in the United Kingdom (UK). Patients were recruited with a clinical diagnosis of PD made by a 
clinician if they fulfilled UK Brain Bank criteria [4]. This was supported by structural and/or functional 
neuroimaging when the diagnosis was not firmly established clinically. Both drug-naïve and treated 
patients, aged 18–90 years were eligible. Recent onset cases (diagnosed in the pre-ceding 3.5 years), 
were recruited between February 2012 and May 2014. Patients were not enrolled if they had severe 
comorbid illness, other degenerative forms of parkinsonism such as multiple system atrophy (MSA), 
or parkinsonism attributable to significant cere-brovascular disease. Patients with drug-induced 
parkinsonism were excluded, but drug-unmasked PD was allowed if justified by abnormal functional 
dopaminergic imaging. Patients whose diagnosis was later revised from PD during regular follow-up 
were excluded from any analysis. 
Any features (signs, symptoms, progression, medication response) that were possibly unusual or 
atypical for PD (and might be early pointers to atypical parkinsonian disorders such as MSA) were 
noted at recruitment, and during follow-up. These cases were included in the main analysis,but 
excluded from the sub-analysis. The study was ap-proved by the West of Scotland Ethics Committee, 
written informed consent was obtained from patients, and procedures followed the Declaration of 
Helsinki. The study was supported by funding from Parkinson's UK. The following features were 
collected in all patients: demographic characteristics, diagnostic features at presentation, medication 
history, Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS UPDRS) scores [9] 
including part 3 scores ‘on’ or ‘off’ medication (‘off’ being defined operationally as below), non-motor 
symptom severity scale (NMSS) [10], Rapid eye movement sleep (REM) sleep behaviour disorder scale 
[11] and the Scale for Outcomes in Parkinson's disease for Autonomic Symptoms (SCOPA-AUT) [12]. 
Motor phenoytpe was categorized according to defined methods [13]. Montreal cognitive assessment 
(MoCA) test scores were adjusted for years of education. Hyposmia was defined using a Sniffin’ Stick 
score of less than or equal to the 10th centile, or at or below the 15th centile on the University of 
Pennsylvania Smell Test score (British version), corrected for age and sex [14]. Presence of low mood 
and depression was assessed using the Leeds Anxiety and Depression Scale (LADS) with a cut-off score 
> 6 [15]. L-dopa equivalent daily dose (LEDD) was calculated using an established formula [16]. 
Vascular risk was calculated by standard methods, using the QRISK2 algorithm, as previously reported 
[17]. Rheumatoid arthritis was included as a vascular risk equivalent, as this confers an increased 
vascular risk [18]. 
At the 2 year visit an L-dopa challenge test was carried out in patients prescribed L-dopa based 
therapy. Patients were asked to omit their usual morning anti-parkinsonian medication. Those co-
prescribed a dopamine agonist omitted this from the night before the L-dopa challenge test (for 
immediate release preparations) and the day before (for once-daily preparations). Assessments were 
undertaken in an ‘off’ state and was repeated 1 h after the patient's usual morning dose of L-dopa, 
expressed as the dose of L-dopa in mg (the L-dopa:decarboxylase ratio was 4:1). The change in MDS 
UDPRS 3 was dichotomised around a 24.5% improvement, which is equivalent to the 30% change in 
the UPDRS 3 score [7] and defined as ‘definite’ when improvement was ≥24.5%, and ‘limited’ when < 
24.5%. 
2.1. Statistical analysis 
A logistic regression model was used with response to L-dopa challenge test as the outcome, and the 
‘limited’ group as the baseline category. Odds ratios, 95% confidence intervals and p-values were 
calculated, before and after adjustment for age, gender and disease duration. Sensitivity analysis was 
implemented for missing values in the outcome and clinical variables. MoCA, UPDRS 3, SCOPA-AUT, 
NMSS, olfaction tests scores, and motor responsiveness to L-dopa, were calculated based on expected 
scores, when at least 80% of the questions were answered in each scale. Any remaining missing values 
were then imputed 10 times, using the multiple imputation chained equations approach. Odds ratios 
and p-values were calculated in the logistic regression models using Rubin's rules. Statistical analysis 
was conducted at 5% significance level, using STATA/MP software version 15.1. 
3. Results 
There were 2006 patients recruited, of whom 37 were excluded either due to disease duration over 
3.5 years (n = 6) or change in diagnosis after recruitment (n = 31). A further 429 did not have data for 
the 2-year visit, leaving 1540 cases, of whom 228 were not prescribed L-dopa at the time of the visit, 
and 305 in whom data collection was incomplete. Accordingly, complete data were available for the 
L-dopa challenge in 1007 cases (Table 1). 
These cases had a mean age of 67.5 years (SD 9.1) at study entry, and the L-dopa response was 
assessed on average 3.4 years (SD 0.9) after diagnosis. A definite L-dopa response was seen in 614 
cases (61.0%). The mean change in MDS UPDRS 3 from pre to post challenge L-dopa dose was 42.0% 
(IQR 33.3, 53.1) in those with a definite response, versus 11.5% (IQR 4.3, 18.2) in those with a limited 
response. Patients who showed a definite L-dopa response were younger (66.3 years, SD 9.3) 
compared to those with a limited response (69.2 years, SD 8.4, p < 0.001). Those with a definite 
response had a lower MDS UPDRS 3 score at study entry (21.0, SD 10.5) than those with a limited 
response (24.7, SD 13.4, p < 0.001) (Fig. 2). Further, those with a definite response showed a smaller 
increment in MDS UPDRS 3 scores over the next 18 months (increase of 3.0 points, SD 10.4) compared 
to an increase of 6.4 points (SD 11.0) in those with a limited response, p < 0.001. The demographic 
and phenotypic characteristics of the cases who undertook the L-dopa challenge test are shown in 
Table 1. Using 24.5% as the cut-off for defining definite responders and limited responders showed a 
bell-shaped curve (Supplementary Fig. 1). The LEDD was not significantly different at study entry 
comparing those with a definite response (317 mg, SD 199) to those with a limited response (305 mg, 
SD 191, p = 0.53). However, the LEDD at the time of the challenge test was higher in those with a 
definite response (541 mg, SD 293) compared to those with a limited response (485 mg, SD 215, p = 
0.01). The proportion of cases with an unequivocal motor response was higher in definite responders 
(25.0%) compared to limited responders (17.8%, p = 0.0106). More patients classified as definite 
responders were prescribed a monoamine oxidase type B inhibitor (34.0%) than those classified as 
limited responders (27.0%, p = 0.0213). The increase in the MDS UPDRS 3 scores in the 283 cases that 
were L-dopa naïve at study entry, from baseline to the ‘off’ score prior to the challenge test, did not 
differ significantly when comparing definite responders to limited responders (p = 0.8, Table 1). There 
were no statistical differences in disease duration, sex, motor subtype, cognitive scores, non-motor 
scores, hyposmia, presence of a rapid eye movement behaviour disorder, constipation, depression or 
autonomic scores between those with a definite versus a limited L-dopa response. 
 
 
Considering comorbid vascular disease and vascular risk factors, only 49.4% of the 89 patients with 
Type 2 diabetes showed a definite L-dopa response. In patients with a prior history of vascular disease 
(n = 149) 53.7% showed a definite L-dopa response. Similarly, in patients with high vascular QRISK2 
scores (n = 345), 56.2% had a definite response to L-dopa, compared to 61.6% with medium vascular 
risk scores (n = 295), and 72.6% with low vascular risk scores (n = 215). However, these observations 
were not statistically significant after adjusting for age, sex, and disease duration. There were no 
significant differences between definite and limited responders for any of the following: prior vascular 
diagnosis (cardiac or cerebral), rheumatoid arthritis, body mass index, the presence of orthostatic 
hypotension, or smoking status. 
The mean dose of L-dopa used in the acute challenge test was not significantly different between 
definite and limited responders, whether considering actual dose, or dose per kilogram body weight 
(Table 2). There was also no significant difference according to fulfilment of MDS diagnostic criteria 
for PD, comparing definite and limited L-dopa responders (Table 2). 
In the sensitivity analysis all 1312 subjects on L-dopa at the 2-year visit were assessed (Fig. 1). Missing 
data were relatively low (< 10%), except in SCOPA-AUT (38.5%), NMSS (22.3%) and L-dopa motor 
response (23.3%). Results did not differ, in any of the key findings, in the sensitivity analysis compared 
to the main analysis (results not shown). 
In the sub-analysis in 949 cases without any unusual or atypical features (94.2% of the 1007 cases) the 
significant findings of the relationship between L-dopa response remained: age (p < 0.001), motor 
severity (p < 0.001), and motor progression (p = 0.001). 
4. Discussion 
Our main finding is that, in a large cohort of prospectively recruited recent onset PD patients, there is 
a substantial variation in the degree of motor response to L-dopa. These results are consistent with 
variation in L-dopa responsiveness in clinical trials and pathological case series [2–4]. In the ELLDOPA 
study in 260 L-dopa treated patients, the average improvement in UPDRS 3 was 27.4% (SD 30.6) at 9 
weeks, and 26.2% (SD 36.4) at 24 weeks [2,3]. Because of the known differences between the UPDRS 
3 and MDS UPDRS Part 3 scores [7] the comparable percentage improvements in the ELLDOPA study 
using the MDS UPDRS 3 would give improvements of 33.6% (SD 37.5) at 9 weeks and 32.1% (SD 44.6) 
at 24 weeks. Variation in the degree of L-dopa response has also been reported in pathologically 
confirmed PD [4]. In 69 of 76 confirmed PD cases in whom the L-dopa response was available, it was 
graded as definite in 29%, good in 39%, limited in 13%, and nil-to-poor in 4% [4]. Taken together, we 
can conclude that the degree of motor improvement in response to L-dopa is subject to significant 
variation, although the reasons for this are unclear. We therefore sought to better define what factors 
may be important in determining the level of response. 
First we examined demographic and disease related features and found that older patients showed a 
less robust response to L-dopa, which has been observed previously [19]. However, we did not confirm 
the previously reported associations of male gender and postural in-stability with lower L-dopa 
response rates [2]. We did however identify a significant relationship between L-dopa responsiveness 
and baseline motor scores, as well as rates of motor progression over an 18-month period. These 
findings are of clinical significance: patients with lower responsiveness to L-dopa have higher motor 
scores, and faster motor progression. A relationship between increasing age and progression of 
disability has been observed previously, and attributed in part to L-dopa non-responsive motor 
symptoms [20]. Further, we observed that more definite responders were prescribed monoamine 
oxidase type B inhibitors, compared to limited responders, which is in keeping with mechanisms and 
responses for this drug class [21]. 
Secondly, given our previous finding of higher motor scores and more cognitive problems in patients 
with vascular disease, or increased vascular risk factors [17], and the known association of vascular 
disease with age, we examined for any relationship between vascular comorbidity and L-dopa 
response in the present study. While we found that both diabetes and higher vascular risk scores were 
associated with lower L-dopa responsiveness, these observations were driven by patient age, so we 
can conclude that vascular comorbidity is not an in-dependent driver of an impaired L-dopa response. 
 
 
  
 
 
 
 
 
 
  
There are several other potential explanations for variation in L-dopa responsiveness. Diagnostic 
inaccuracy is known to occur in cases with an early clinical diagnosis of PD [4,5], and a poor or absent 
L-dopa responses in such erroneously diagnosed cases would affect the response levels reported. We 
controlled for this confounding factor in 2 ways, firstly by prospective collection of structured 
information of individual clinical features that might be atypical for PD, with analysis after excluding 
these cases, and secondly by considering the L-dopa response in relation to fulfilment of MDS 
diagnostic criteria [22]. We did not find major differences using either approach, compared to the 
main analysis: an additional 1.3% of cases had a definite response after excluding possible atypical 
features, while there was no indication of differences in L-dopa response according to categorisation 
by MDS criteria into ‘established PD’ or ‘probable PD’, versus those not fulfilling PD criteria. Taken 
together, it appears that diagnostic error is not a major contributor to the variation observed in L-
dopa responsiveness in our study. 
The dose of L-dopa used to assess responsiveness is clearly important and is another source of 
variation in our study and others. We used the patient's standard morning L-dopa dose in the acute 
challenge test, which may have underestimated the response to L-dopa in some cases. However, we 
reasoned that this relatively lower dose was ap-propriate, as it would be better tolerated by patients. 
Furthermore it is an approach that has been adopted in other similar observational studies [23], and 
in fact we found that the dose used in our challenge tests was not significantly different between 
definite and limited responders. However, the LEDD at the time of the challenge test was significantly 
lower (around 50 mg per day) in patients with a limited response compared to those with a definite 
response, while there was no difference in LEDD between the groups at study entry. This raises the 
possibility that some patients are under-dosed despite worsening motor severity. Other factors may 
influence the drug dose given to some patients, such as neuropsychiatric features [24]. Our findings 
suggest that clinicians are more likely to increase dopamine replacement therapy doses when there is 
a stronger L-dopa response. 
Earlier literature reported acute challenge tests with higher L-dopa doses. For example, a unit dose of 
250 mg L-dopa gave a positive response (i.e. a reduction in motor score equivalent to the threshold 
used in the present report) in 39 of 55 early PD cases (70.9%) [8]. An earlier systematic review of 
dopaminergic challenge tests in PD, which included 2 studies using acute L-dopa challenges, calculated 
that 69% of de novo PD and 76% of established PD exceeded this same threshold of response, but this 
combined results using 250 mg L-dopa in 45 cases, 200 mg L-dopa in 1 case, and 100 mg L-dopa in 21 
cases [25]. Direct comparison with our findings is difficult, as those previous studies used a mixture of 
tasks and degrees of improvement to assess response (e.g. walking speed, tapping tasks, and 15–20% 
improvement in motor scores) and only 1 of the 4 studies assessed the acute L-dopa challenge 
response using UPDRS 3 scores [25]. Assessing the effect of escalating L-dopa challenge test doses is 
the subject of few reports: in one study 16 out of 22 cases (72.7%) responded at 100 mg L-dopa, which 
increased by 1 case (to 77.2%) when the L-dopa challenge dose was increased to 200 mg [26]. Further 
support of the impact of the L-dopa dose comes from the ELLDOPA study [3]. Considering those cases 
that had more than a 10% improvement in motor score after 24 weeks of L-dopa treatment compared 
to baseline, this accounted for 76.5% of cases prescribed 300 mg L-dopa per day, compared to 89% of 
cases pre-scribed 600 mg L-dopa per day [2]. 
The other major consideration in L-dopa responsiveness relates to known inter-subject variability in 
its pharmacokinetics. Variations in body weight [27], gut absorption [28] and gender [29] are all 
reported as potential contributors to response variations. The known higher bioavailability of L-dopa 
in postmenopausal women [29] did not, however, translate to a gender differences in our study. There 
are several other biological mechanisms that influence pharmacokinetics and pharmacodynamics of 
L-dopa at the cellular level. Higher levels of erythrocyte catechol-O-methyltransferase (which 
catabolises L-dopa) may impair the L-dopa response [30], and genetic variants of this [31] and other 
enzymes, including dopa decarboxylase [32] and monoamine oxidase type B [31], are emerging as 
contributors to later motor fluctuations associated with L-dopa. We consider it likely that genetic in-
fluences in the pharmacodynamic and pharmacokinetic handling of L-dopa will also influence the 
motor response to this drug even at earlier disease stages. The results of these detailed genetic 
analyses (including data about motor complications from our ongoing observations) will be the subject 
of a later report from our group. 
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